Takeda

Phone: +81 3-3278-2111

Web: https://www.takeda.com

Native name	武田薬品工業株式会社
Romanized name	Takeda Yakuhin Kōgyō kabushiki gaisha
Formerly	Chobei Takeda & Co., Ltd. (1925-1943) Takeda Pharmaceutical Industries, Ltd. (English name only 1943-1961) Takeda Chemical Industries, Ltd. (English name only 1961-2004)
Type	Public KK
Traded as	TYO: 4502 NAG: 4502 FSE: 4502 NYSE: TAK Nikkei 225 component (TYO) TOPIX Core30 component (TYO)
Industry	Pharmaceuticals
Founded	Doshomachi, Osaka, Japan (June 12, 1781 (1781-06-12))
Founder	Chobei Takeda I
Headquarters	Nihonbashi, Chuo, Tokyo, Japan
Key people	Yasuchika Hasegawa (Chairman of the Board) Christophe Weber (President & CEO)
Revenue	¥1,770,531 million (FY 2018)
Operating income	¥241,789 million (FY 2018)
Net income	¥186,886 million (FY 2012)
Total assets	¥4,106,463 billion (FY 2018)
Total equity	¥1,997,424 billion (FY 2018)
Owner	Nippon Life (2.24%), BNY Mellon(5.39%) JPMorgan Chase(3.50%) State Street Corporation(1.50%)
Number of employees	49,578 (2019) (18,378) in United States (5,350) in Japan
Website	takeda.com (Global website)

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 230 years of distinguished history in Japan. We have presence in approximately 80 countries, with leading positions in Japan and the U.S., respectively the third and first largest pharmaceutical markets in the world. We will deliver highly innovative medicines and transformative care for more people globally.

For detailed contact information visit location pages below.